Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

New cancer drugs often cause skin and nail problems.

Ruxolitinib can cause a delayed skin reaction on the nose.

Blocking RANK signaling might help treat metastatic melanoma, but more research is needed.

Indinavir therapy can cause reversible skin, hair, and nail darkening.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

Cepharanthine may help treat gastric cancer by causing cancer cell death and affecting energy use.

Gefitinib can cause scalp skin issues and permanent hair loss.

The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.

Ruxolitinib cream effectively targets and treats inflammatory skin diseases.

Tofacitinib is effective and safe for treating severe alopecia areata.

Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.

Nilotinib can cause skin issues like red bumps and hair loss.

Pulsed electric field treatment may help shrink untreated liver tumors.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Tofacitinib may help hair regrowth in familial alopecia areata with immune issues, but more research is needed.

MITF+ melanoma patients are more likely to have multiple melanomas and unique skin patterns.

EGFR inhibitors can cause yellowish skin eruptions.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Ruxolitinib cream may help treat severe hair loss in children.

Securinine and ajmaline may effectively treat liver cancer, with securinine being less toxic to normal cells.

Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.

Some new drugs show potential for treating blood cancers but have serious side effects and need more research.

Clofazimine effectively treated ashy dermatosis in a patient.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.